Experiment Overview
| Repository ID: | FR-FCM-ZZDR | Experiment name: | FIGURE 1_Optimization of rhabdomyosarcoma disseminated disease assessment by flow cytometry | MIFlowCyt score: | 29.25% |
| Primary researcher: | Ana Almazan | PI/manager: | Ana Almazan | Uploaded by: | Ana Almazan |
| Experiment dates: | 2011-05-29 - 2013-06-11 | Dataset uploaded: | Jul 2014 | Last updated: | Aug 2014 |
| Keywords: | [flow cytometry] [Rhabdomyosarcoma] [PAX3] [minimal residual disease] [soft tissue sarcomas] [pediatric cancer.] | Manuscripts: | [25155056] |
|
|
| Organizations: |
Vall d'Hebron Research Unit, Barcelona, (Spain)
|
||||
| Purpose: | PAX3 labeling was assayed by flow cytometry in a panel of RMS and non-RMS cell lines to assess the specificity of this marker. | ||||
| Conclusion: | PAX3 could be considered a highly sensitive additional marker for MRD in RMS. | ||||
| Comments: | None | ||||
| Funding: | Not disclosed | ||||
| Quality control: | For flow cytometry analysis, samples treated with the appropriate IgG were used as a negative control. Cell lines expressing high PAX3 levels were used as positive controls of PAX3 detection. | ||||
